argenx Offers $1.15 Billion to Acquire Remaining Unnatural Products Shares
Key Facts
argenx announced a definitive agreement on November 9, 2026, to acquire all remaining shares in Unnatural Products, in which it already holds a minority stake, in a deal with total consideration that could reach about $1.15 billion. The company said the agreement brings together its antibody-engineering expertise with UNP’s peptide expertise to expand the potential to develop oral or long-acting treatments for immune-mediated diseases. The consideration includes $550 million in cash at closing, plus contingent payments of up to $595 million upon achievement of specified development and regulatory milestones. The announced value is therefore not a fixed cash amount paid entirely at closing; the contingent portion depends on those milestones being met. The company’s announcement was listed at 07:00 Central European Time on the day it was released.
argenx will pay the initial $550 million in cash from available funds when the deal closes, under the terms announced by the company. The additional payments, capped at $595 million, depend on reaching specified development and regulatory milestones. Total potential consideration would reach about $1.15 billion if those conditions are met, according to the company. Under this structure, more than half of the potential value is tied to later milestones rather than paid upfront. The final value UNP may receive will therefore depend on development progress and satisfaction of the agreed regulatory criteria.
The deal’s strategic rationale centers on adding a platform for discovering macrocyclic peptides to argenx’s immune-research capabilities. Chief Executive Karen Massey said UNP’s capabilities in these peptides are "highly complementary to our antibody engineering, opening new possibilities for oral and long-acting medicines." The company also described the deal as combining its antibody-engineering expertise with UNP’s peptide expertise to expand the potential to develop treatments for immune-mediated diseases. Bringing the two fields together gives the company different research tools in pursuit of one direction: exploring immune treatments that can be taken orally or last longer. The company did not describe the deal as an expansion of manufacturing plans; its announcement focused on the discovery platform and research capabilities.
argenx describes UNP’s platform as addressing the medicinal chemistry challenges of macrocyclic peptides by combining parallel experimentation and machine learning. The company is working on treatments targeting targets that are difficult to address with drugs, according to argenx’s statement. This specialization complements the antibody engineering developed by argenx, the point of integration Massey highlighted in her description of the deal. The companies had previously worked together in a multi-target research collaboration that lasted more than two years before announcing the agreement on November 9. That prior collaboration provides context for the acquisition: it follows existing joint work rather than a research relationship that began with the announcement.
UNP Chief Executive and co-founder Cameron Pye said argenx provides "the ideal environment to accelerate and expand this vision to bring innovative treatments to patients." His statement reflects the acquired company’s focus on continuing to develop its platform within the group, while argenx said its research expertise would complement UNP’s peptide capabilities. The boards of both companies approved the deal, according to the announcement. UNP’s team and leadership are expected to continue working from the company’s site in Santa Cruz, California, after the acquisition closes. The site will become argenx’s peptide discovery center, while the company will add its clinical development and commercialization capabilities.
argenx expects to complete the acquisition by the end of 2026, subject to customary closing conditions, following approval by both companies’ boards. Until closing, payments tied to development and regulatory milestones remain a contingent part of the potential consideration, under the announced deal structure. After closing, UNP’s team and leadership will continue working from Santa Cruz, which will become argenx’s peptide discovery headquarters. argenx also plans to add its clinical development and commercialization capabilities to the research platform, according to its statement. The information announced by the companies did not give a more precise completion date than the end of the year.